Results from the Phase III ATTAIN-1 trial (NCT05869903) showed that the highest dose of orforglipron achieved an average ...

In the Phase III TRIUMpH program, tegoprazan met primary endpoints and outperformed lansoprazole in maintaining healing of ...

Jon Walsh, founder, chief scientific officer, Unlearn, explains how digital twins provide patient-level predictions that ...

In this video interview, Luke Wilson, senior director, biotech, pharma services at Thermo Fisher Scientific, outlines the key ...